CMOS

Novartis to Manufacture Carisma Therapeutics' Anti-HER2 CAR-Macrophage Therapy

Novartis has signed on as a third-party CMO to manufacture Carisma's autologous cell therapy, which is in early trials for HER2-overexpressing solid tumors.

Breaking News

Candel Therapeutics to Raise $80M in Public Stock and Warrants Offering
Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel
Boundless Bio Ends Trial of BBI-825 in Patients With Certain Cancer Resistance Mutations
In Brief This Week: Lantern Pharma, AstraZeneca, Genesupport, UniQure, PanGIA Biotech
Leapfrog Bio to Begin Phase II Trial of Synthetic Lethal Candidate in Solid Tumors
Natera Enrolls First Patients in Phase III SAGITTARIUS Colon Cancer Trial

CMOS

Novartis to Manufacture Carisma Therapeutics' Anti-HER2 CAR-Macrophage Therapy

Candel Therapeutics to Raise $80M in Public Stock and Warrants Offering

Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel

Boundless Bio Ends Trial of BBI-825 in Patients With Certain Cancer Resistance Mutations

In Brief This Week: Lantern Pharma, AstraZeneca, Genesupport, UniQure, PanGIA Biotech

Leapfrog Bio to Begin Phase II Trial of Synthetic Lethal Candidate in Solid Tumors

Natera Enrolls First Patients in Phase III SAGITTARIUS Colon Cancer Trial